The recommendation follows the approval of capivasertib by the Medicines ... with Astex Pharmaceuticals to design small-molecule inhibitors which would target AKT, based on its 3D structure. In 2005, ...

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue ...

A team at UC San Francisco and Gladstone Institutes has developed new drug candidates that show great promise against the ...

A Systematic Review Eligible patients had AKT1 E17K–mutated metastatic tumors that progressed with standard treatment and received capivasertib 480 mg orally twice daily for 4 days on and 3 days off ...

which was involved in the drug development research for capivasertib, said it “strongly welcomed” the decision. Nicholas Turner, professor of molecular oncology at the ICR and consultant ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival Eligible patients had AKT1 E17K–mutated metastatic tumors that progressed with standard ...

Scientists described the approval of capivasertib by the National Institute for Health and Care Excellence (NICE) as a "landmark moment".

She says that capivasertib, which she has been able to access via private healthcare, has not only extended her life but improved its quality with fewer side effects than previous medications.

Chemists have confirmed a 67-year-old theory about vitamin B1 by stabilizing a reactive molecule in water — a feat long ...

Professor Nicholas Turner, from the Institute of Cancer Research, tells Sky News that capivasertib is a "great success story for British science", adding: "It doubles how long hormone therapy ...